Fusion Clinical Research
Fusion Clinical Research is a South Australian CRO that runs Phase II-IV clinical trials for global pharma, biotech, and CROs from its Norwood facility, recruiting via a 10,000+ participant database and a national GP/specialist referral network.
- Company typePrivate
- Founded2018
- HeadquartersNorwood, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Fusion Clinical Research does
Fusion Clinical Research is a South Australia-based contract research organisation (CRO) that operates Phase II-IV clinical trials on behalf of global pharmaceutical companies, biotechnology firms, and CROs. Founded in 2018 as the later-phase division of CMAX Clinical Research, one of Australia's oldest Phase I units, Fusion conducts its work from a purpose-built facility in Norwood, Adelaide, and supports trials across therapeutic areas including vaccination, weight management, cardiovascular disease, COPD, hypertension, and respiratory infections.
The company's core service is end-to-end late-phase trial execution: patient recruitment, protocol delivery, data management, quality assurance, and close-out activities, staffed by an in-house team of doctors, nurses, scientists, and technicians. Recruitment is underpinned by a database of more than 10,000 active participants and a referral network spanning GPs and specialists across multiple disciplines (cardiology, dermatology, neurology, endocrinology, ophthalmology, immunology, radiology, pain, bariatrics, and lipidology).
Fusion monetises through professional-services contracts with sponsors and CROs, leveraging Australia's Clinical Trials Notification (CTN) scheme (4-8 week review cycles) and the R&D Tax Incentive (up to 43.5% rebate) to improve economics. The business development function sells directly into enterprise pharma and global CRO accounts, with a public sponsor roster that includes Sanofi, Eli Lilly, AstraZeneca, GSK, AMGEN, IQVIA, ICON, PPD, and Novotech. Revenue is not disclosed; the legal entity is CMAX Clinical Research Pty Ltd.
Fusion Clinical Research firmographics
Firmographics- Name
- Fusion Clinical Research
- Legal name
- CMAX Clinical Research Pty Ltd
- Website
- https://fusiontrials.com.au
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Fusion Clinical Research is a South Australian CRO that runs Phase II-IV clinical trials for global pharma, biotech, and CROs from its Norwood facility, recruiting via a 10,000+ participant database and a national GP/specialist referral network.
- Ownership category
- akta.pro rank
Fusion Clinical Research industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industry
- Investigator & Site Training / GCP Support (HLAGACAF)
Keywords
Where Fusion Clinical Research is headquartered
LocationHeadquarters
- HQ city
- Norwood
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Fusion Clinical Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Clinical Trial Services: Fusion Clinical Research generates revenue by conducting Phase II-IV clinical trials for pharmaceutical companies, biotech firms, and CROs. Services include trial design support, patient recruitment through their GP network and database, trial execution, data management, and quality assurance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | F03825 Weight Management Trial: $75 per clinic visit + $48 for fasting visits |
| Other | Pay-as-you-go | F03725 Weight Management Trial: $106 per in-clinic visit, $53 per telehealth visit, $51 per DEXA scan |
| Other | Pay-as-you-go | F04026 Strep Throat & Rheumatic Fever Trial: $3,450 total |
| Other | Pay-as-you-go | F04126 Oral Weight Management Trial: Travel expense reimbursement only |
| Other | Pay-as-you-go | F03225 COPD Trial: Reimbursement available (amount not specified) |
| Other | Pay-as-you-go | F03625 Cardiovascular Trial: $75 per site visit + $48 for fasting visits |
| Other | Pay-as-you-go | F02724 Cardiovascular Trial: $100 per visit |
| Other | Pay-as-you-go | F01924 Pneumococcal Vaccine Trial: $975-$1,275 depending on cohort |
| Other | Pay-as-you-go | F01123 Lorundrostat Hypertension Trial: $60 per visit |
| Other | Pay-as-you-go | C02722 Hypertension Trial: $7,330 total |
| Other | Pay-as-you-go | C04723 COPD Trial: $6,320 total |
| Other | Pay-as-you-go | F03525 Heart & Kidney Health Trial: $75 per visit |
| Other | Pay-as-you-go | F02925 Respiratory Viruses Trial: $2,200 total |
| Other | Pay-as-you-go | F00723 Obesity & Cardiovascular Disease Trial: $60 per visit |
| Other | Pay-as-you-go | F01023 Weight Management Trial: $120 per visit + $25 for fasting |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Fusion Clinical Research product offering
Product offeringCore offering
Fusion Clinical Research conducts Phase II-IV clinical trials for pharmaceutical companies, biotechnology firms, digital health companies, and Contract Research Organisations. Its two core service lines are Vaccination Clinical Trials and Medical Condition and Disease Clinical Trials, delivered end-to-end from start-up through close-out, including patient recruitment via an in-house database of 10,000+ participants and a GP/specialist referral network, trial management, data services, and quality assurance aligned with international GCP standards.
Product overview
Fusion Clinical Research is South Australia's leading later phase clinical trial operator, launched in 2018 as a division of CMAX Clinical Research. The company operates two core service lines: Vaccination Clinical Trials (covering pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines) and Medical Condition and Disease Clinical Trials (spanning mental health, sleep disorders, cardiac, obesity/metabolic disorders, diabetes, and dermatology). The company conducts Phase II-IV clinical trials from its purpose-built facility in Norwood, Adelaide, offering end-to-end trial services including patient recruitment via a database of more than 10,000 participants, trial management, data services, and quality assurance. Fusion's network of General Practitioners and Specialists enables connection to patients for local and international pharmaceutical, biotech, digital health, and clinical research organisations.
Differentiator
Problem solved
Functional benefit
Products and services
- Vaccination Clinical Trials End-to-end Phase II-IV clinical trial services for vaccine sponsors, evaluating investigational vaccines including pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines (COVID-19/influenza). Targeted at pharmaceutical companies, biotech firms, and CROs seeking vaccine trial execution in Australia.
- Medical Condition and Disease Clinical Trials End-to-end Phase II-IV clinical trial services across therapeutic areas including mental health, sleep disorders, cardiac, obesity and metabolic disorders, diabetes, and dermatology. Targeted at pharmaceutical companies, biotech firms, digital health companies, and CROs requiring late-phase trial execution in Australia.
- Weight Management Trials Later phase clinical trials evaluating investigational weight management treatments including oral medications and subcutaneous injections in adults aged 18 or older who are overweight. Targeted at pharmaceutical and biotech sponsors developing obesity therapeutics.
- Cardiovascular Trials Clinical trials testing investigational cardiovascular medicines for adults with elevated Lipoprotein(a) levels or cardiovascular disease risk. Targeted at pharmaceutical and biotech sponsors developing cardiovascular therapeutics, including studies such as F03625.
- COPD Trial (F03225) Clinical research study testing an investigational medication for moderate to very severe chronic obstructive pulmonary disease (COPD) in adults 40+ with COPD, with 9 visits over approximately 32 weeks. Targeted at pharmaceutical sponsors developing respiratory therapeutics.
- Strep Throat & Rheumatic Fever Vaccine Trial (F04026) Clinical research study evaluating an investigational vaccine to prevent Streptococcal infections in adults aged 18-40, with 9 visits over approximately 9 months and total participant compensation of $3,450 upon completion. Targeted at pharmaceutical vaccine sponsors.
Quantifiable outcome
- 4-8 week review cycle for clinical trial approvals under Australia's CTN scheme
Companies that use Fusion Clinical Research
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Fusion Clinical Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Fusion Clinical Research partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- CMAX Clinical ResearchcoreFusion Clinical Research is a division of CMAX Clinical Research Pty Ltd. Fusion was launched in 2018 as the Phase II-IV Division to CMAX Clinical Research, expanding the service to later phase trials. CMAX is described as one of Australia's oldest and most successful Phase I clinical trials units. All privacy policies and corporate governance reference the parent company CMAX.
- SanofiminorGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- PPD (Pharmaceutical Product Development)minorGlobal CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- NovotechminorAPAC-focused CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- IQVIAminorHealthcare technology and analytics company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- ICONminorGlobal CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- GSK (GlaxoSmithKline)minorGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- Eli LillyminorGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- AstraZenecaminorGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
- AMGENminorGlobal biotechnology company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Fusion Clinical Research competitors and assessment
Company assessmentDirect peers
- Linear Clinical Research: Perth-based Australian clinical trial site conducting Phase I-IV trials with an active participant database. Most directly comparable to Fusion as a same-country, similar-phase late-phase operator competing for global sponsor placements in Australia.
- CMAX Clinical Research: Fusion's parent company and one of Australia's oldest Phase I clinical trials units, based in Adelaide. Operates the same single-site Adelaide infrastructure and shares governance, making it the closest corporate and operational peer.
- Nucleus Network: Australian early-phase clinical trial operator with sites in Melbourne and Brisbane. Comparable as a domestic Phase I/II competitor targeting the same pool of global sponsors and CRO partnerships, though with earlier-phase focus than Fusion.
- Q-Pharm: Brisbane-based early-phase clinical trials unit focused on Phase I and first-in-human studies. Comparable as an Australian dedicated clinical trial site, with overlap in sponsor and CRO relationships even though its phase mix differs from Fusion.
Broad incumbents
- Novotech: APAC-focused CRO headquartered in Australia with extensive Phase I-IV site management. Both a Fusion client and the most direct regional competitor for late-phase trials across Australia and the broader Asia-Pacific region.
- PPD (Thermo Fisher Scientific): Global CRO acquired by Thermo Fisher Scientific, providing full-service clinical development across all phases. Fusion customer and broad incumbent competing for sponsor trial placements worldwide.
- IQVIA: Global CRO and healthcare data/analytics company that is both a Fusion client and a broad incumbent operating its own global site network. Comparable as a counterparty in clinical trial outsourcing decisions and as a benchmark for global CRO capabilities.
- ICON plc: Global CRO with a broad Phase I-IV site network. Listed Fusion customer and a broad incumbent competing for the same late-phase sponsor programs at global scale.
- Parexel International: Global CRO offering full-service Phase I-IV clinical development and site services. Comparable as a broad incumbent competing for the same global late-phase trial mandates that Fusion accesses through sponsor and CRO partnerships.
Regional players
- Bellberry Limited: South Australia-based Human Research Ethics Committee supporting Australian clinical trials. Not a direct site competitor but an institutional enabler whose review timelines shape how Fusion and other Australian sites operate in the same regulatory pathway.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Fusion Clinical Research social profiles
Digital presenceFusion Clinical Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fusion Clinical Research leadership team
Management profileNumber of profiles
Profiles10 records
Fusion Clinical Research funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fusion Clinical Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fusion Clinical Research
What does Fusion Clinical Research do?
Fusion Clinical Research conducts Phase II-IV clinical trials for pharmaceutical companies, biotechnology firms, digital health companies, and Contract Research Organisations. Its two core service lines are Vaccination Clinical Trials and Medical Condition and Disease Clinical Trials, delivered end-to-end from start-up through close-out, including patient recruitment via an in-house database of 10,000+ participants and a GP/specialist referral network, trial management, data services, and quality assurance aligned with international GCP standards.
Is Fusion Clinical Research a public or private company?
Fusion Clinical Research is a private company. It is classified as corporate owned and is currently operating.
When was Fusion Clinical Research founded?
Fusion Clinical Research was founded in 2018. It employs 11 to 50 people.
Where is Fusion Clinical Research based?
Fusion Clinical Research is headquartered in Norwood, Australia, in the Oceania region.
How does Fusion Clinical Research make money?
One revenue line is on record: clinical Trial Services.
Who are Fusion Clinical Research's main competitors?
Direct peers on record are Linear Clinical Research, CMAX Clinical Research, Nucleus Network and Q-Pharm. Broad incumbents are Novotech, PPD (Thermo Fisher Scientific), IQVIA, ICON plc and Parexel International. Bellberry Limited is listed as a regional player.
Does Fusion Clinical Research have an API?
No public API is recorded for Fusion Clinical Research.
What industry is Fusion Clinical Research in?
Fusion Clinical Research's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAF, Investigator & Site Training / GCP Support. Its NAICS code is 5417 and its SIC code is 8731.